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Preface
The prokaryotic type II clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 
system is rapidly revolutionizing the field of genetic engineering, allowing researchers to alter the 
genomes of a large variety of organisms with relative ease. Experimental approaches based on this 
versatile technology have the potential to transform the field of cancer genetics. Here we review 
current approaches based on CRISPR-Cas9 for functional studies of cancer genes, with emphasis 
on its applicability for the development of the next-generation models of human cancer.
Cancer is a disease characterized by multiple genetic and epigenetic alterations in oncogenes 
and tumor suppressor genes1. Therefore, experimental approaches to manipulate the 
genomes of normal and cancer cells are critical for modeling the disease as well as 
systematically studying the many genes involved in the process. Decades of research and 
development of genome engineering technologies have made it possible to precisely delete, 
or otherwise modify, specific DNA sequences in the genomes of cells in culture or of animal 
models to explore the role of genes implicated in cancer initiation, progression and 
therapeutic response. Pioneering work by Mario Capecchi, Oliver Smithies, and others on 
gene targeting in embryonic stem (ES) cells via homologous recombination2–4 provided the 
scientific community the means to generate numerous genetically-engineered mouse models 
(GEMMs) harboring precise mutations in tumor suppressors and oncogenes as well as cell 
lines with defined loss-of-function or gain-of-function alterations in genes that are relevant 
to cancer biology. Moreover, this technology has been successfully employed in 
combination with site-specific recombinases, such as Cre and Flp, to generate conditional 
alleles of a large number of cancer genes5. Although a mainstay of cancer genetics over the 
past two decades, these gene modification approaches have been limited by the relatively 
low efficiency of gene targeting by homologous recombination and the time required for ES 
cell manipulation and subsequent mouse breeding.
One strategy to increase the efficiency of gene targeting is to introduce DNA double-strand 
breaks (DSBs) at the genomic locus of interest6–10. These DSBs are repaired by cellular 
DNA repair pathways, particularly by the error-prone non-homologous end joining (NHEJ) 
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pathway, which frequently leads to insertion or deletion mutations (indels). DSBs are also 
repaired by the homology-directed repair (HDR) pathway, which can mediate precise DNA 
modifications in the presence of exogenous donor DNA templates (Figure 1A). Subsequent 
studies based on these initial observations led to the development of improved site-specific 
genome engineering methods, of which zinc finger nucleases (ZFNs)10–12 and transcription 
activator-like effector nucleases (TALENs)13–16 have been extensively utilized in a variety 
of cell types and organisms (reviewed in17,18). ZFNs and TALENs greatly facilitated precise 
genome engineering; however, their widespread adoption has been limited by the cost and 
complexity of designing these custom-built endonucleases.
The recently described prokaryotic clustered regularly interspaced short palindromic repeats 
(CRISPR)-Cas system and the successful implementation of the Streptococcus pyogenes-
derived type II CRISPR-Cas9 system in mammalian cells by the Zhang19, Church20, 
Doudna21 and Kim22 groups has rapidly changed the landscape of genome engineering by 
addressing many of the limitations of earlier methods. This highly versatile system, which is 
derived from a prokaryotic adaptive immune system, is composed of two biological 
components: the RNA-guided DNA endonuclease Cas9 and a chimeric single guide RNA 
(sgRNA). The sgRNA molecule contains both a CRISPR RNA (crRNA) component and a 
trans-activating crRNA (tracrRNA) component, which binds to Cas9 and directs it to a 
genomic sequence of interest via base pairing to the target sequence23 (Figure 1B). The only 
criterion defining the target sequence is that it be adjacent to a protospacer adjacent motif 
(PAM), consisting of either an NGG or NAG trinucleotide24 for S. pyogenes-derived Cas9 
(of note, other Cas9 orthologues recognize different PAM sequences25,26). By simply 
combining the expression of Cas9 with an sgRNA complementary to a target DNA 
sequence, one can achieve high efficiency cleavage of the target, leading to DSBs, which 
then get repaired via NHEJ or HDR (Figure 1B). Numerous studies published over just the 
last few years have demonstrated efficient gene disruption and gene modification in a 
variety of cells and organisms via CRISPR-Cas9-mediated NHEJ or HDR, respectively 
(reviewed in27).
In this Progress article, we discuss several recent applications of the CRISPR-Cas9 system, 
with particular emphasis on approaches that promise to transform the field of cancer biology 
by facilitating the engineering of normal and cancer genomes.
Rapid modeling of genetic events
In the current era of cancer genomics, several large-scale cancer genome sequencing efforts 
have produced an expanding catalogue of the genetic alterations present in human tumors28. 
Amongst a background of so-called passenger mutations, which are presumed not to directly 
affect the tumorigenic process, driver mutations directly or indirectly promote the 
transformation of normal cells to cancer cells through mutational activation of oncogenes 
and/or inactivation of tumor suppressor genes. Oncogenes are typically activated via gain-
of-function mutations whereas tumor suppressor genes are usually inactivated via loss-of-
function mutations.
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Moderate to large-scale functional genetic studies aimed at dissecting the role of putative 
oncogenes and tumor suppressor genes in cell culture, xenografts, allografts and, in some 
cases, transgenic mouse models have traditionally relied on cDNA-based overexpression 
and RNA interference (RNAi)-mediated knockdown approaches. While these approaches 
have led to many important discoveries in cancer biology over the last several years, they 
have a number of important limitations. First, cDNA-based expression systems can lead to 
supraphysiological levels of gene expression29, which might cause aberrant and artifactual 
effects on signaling pathways and cell biological processes. RNAi-based inactivation 
approaches are limited by the uncertainty of the degree of gene silencing and the stability of 
the inhibition. This is not problematic for some targets or experimental protocols, but for 
others complete and permanent inactivation is required to obtain consistent results. RNAi-
based approaches can also suffer from substantial off-target effects. The deployment of the 
CRISPR-Cas9 system for targeted modification of endogenous loci offers a rapid method for 
overcoming these limitations. In addition to simplifying the study of oncogenes and tumor 
suppressor genes, the CRISPR-Cas9 system also allows for rapid discrimination between 
driver and passenger mutations.
Permanent Cas9-mediated modification of single or multiple endogenous loci can be 
achieved via transient or stable delivery of the CRISPR components. Several groups have 
reported successful editing of endogenous genes in cells in culture via transient transfection 
of plasmid DNA encoding Cas9 and sgRNAs19–22 or Cas9-sgRNA ribonucleoprotein 
complexes (RNPs)30,31. Alternatively, CRISPR components can be stably delivered into 
cells through the use of retroviruses or lentiviruses32,33. To engineer loss-of-function 
mutations, one relies on NHEJ, which often results in the generation of indels near the Cas9 
cleavage site that frequently lead to frameshift mutations. Engineering gain-of-function 
mutations requires the inclusion of an HDR template in the form of single-stranded or 
double-stranded DNA carrying the desired mutation (Figure 1B and Box 1). Transient 
expression of the CRISPR components offers the advantage of a hit-and-run strategy, which 
should allow for unlimited serial editing of endogenous genes without the need of multiple 
viral integrations or continuous expression of CRISPR components. Cell lines carrying one 
or more targeted mutations can then be tested using a battery of cell-based and in vivo assays 
to examine the effects of the mutation(s) on cancer-associated phenotypes. This approach 
can be used on established cancer cell lines, primary cell lines obtained from mouse or 
human origins, as well as patient-derived xenografts and organoid cultures, among others 
(Box 1). Moreover, this technology should allow for systematic analysis of epistatic 
interactions and comprehensive dissection of oncogenic signaling pathways via sequential or 
multiplex gene editing. In addition to allowing the functional characterization of true cancer 
genes, such studies can also help rule out a functional effect of a passenger mutation on 
cancer initiation and progression. Several review articles27,34 have recently described in 
detail most applications of the CRISPR-Cas9 system for genome engineering. We have 
summarized these applications in Boxes 1–3 and will focus below on the utility of this 
technology for generating animal models for the study of cancer genes in vivo.
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Rapid generation of mouse models
Genetically-engineered mouse models (GEMMs)5 and non-germline GEMMs (nGEMMs)35 
of cancer have played a critical role in uncovering several fundamental aspects of tumor 
initiation, maintenance and progression. In addition, they have emerged as faithful models 
with which to test a variety of anti-cancer agents, as well as for uncovering mechanisms of 
drug resistance36,37. However, generating GEMMs is a slow and expensive process, 
requiring complex ES cell manipulation and/or pronuclear injection, as well as extensive 
mouse husbandry to obtain animals harboring the alleles of interest35. nGEMMs of cancer 
can simplify this process by bypassing the need for complex genetic crosses through the 
serial re-targeting of ES cells35. Nevertheless, the inability to simultaneously introduce 
multiple genetic modifications in mice or ES cells remains a considerable barrier.
Jaenisch and colleagues have recently demonstrated that the CRISPR-Cas9 system can be 
utilized to simultaneously disrupt up to eight alleles in mouse ES cells in a single step38. 
Furthermore, they reported efficient simultaneous disruption of two genes in single-cell 
mouse embryos and the subsequent one-step generation of double knockout animals38. This 
group also demonstrated efficient simultaneous HDR-mediated genome editing of two 
endogenous genes38. In a subsequent study, they extended their CRISPR-Cas9 methods for 
rapidly generating mice carrying conditional Cre/loxP-based alleles and reporter alleles, as 
well as using pairs of sgRNAs to generate mice carrying small deletions39 (Box 1). These 
studies have demonstrated the ease with which ES cells or mice harboring multiple gain-of-
function and loss-of-function mutations can be generated, an advance that has opened the 
door for the development of novel GEMMs and nGEMMs of cancer with unprecedented 
speed and precision. Indeed, we predict that there will be an explosion of novel GEMMs and 
nGEMMs harboring uniquely complex genetic alterations that will allow for detailed 
analysis of several stages of tumor evolution with unprecedented speed and efficiency 
(Figure 2A). For example, CRISPR-mediated engineering will allow for rapid generation of 
large repositories of ES cell lines harboring multiple combinations of constitutive or 
conditional mutations in oncogenes and tumor suppressor genes, as well as large 
chromosomal rearrangements that will capture some of the genetic heterogeneity that is 
characteristic of human cancer genomes. These ES cell lines can be utilized to generate 
GEMMs and nGEMMs of cancer harboring multiple distinct mutant genotypes, which will 
be highly valuable for testing new therapeutic regimens and for personalized oncology 
efforts.
It is important to note that the majority of mouse cancer models have been based on a rather 
limited number of mutant genes or alleles, such as the G12D or G12V mutations in the Kras 
oncogene40,41. The CRISPR-Cas9 system will allow for systematic generation of models 
harboring multiple oncogenic alleles, making it possible to investigate allele-specific 
consequences in tumor progression and therapeutic response. Highly systematic and 
multiplexable approaches for HDR-mediated editing of specific genomic regions, such as 
the methods developed by the Shendure laboratory42, will facilitate rapid analysis of 
‘hotspot’ regions with various combinations of mutations and subsequent generation of 
GEMMs and nGEMMs.
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Beyond new model development, the CRISPR-Cas9 system can also be used to refine 
existing models of cancer. ES cell lines derived from well-studied GEMMs can be readily 
reengineered to harbor additional constitutive or conditional mutant alleles of oncogenes and 
tumor suppressor genes43 (Figure 2A). Thus, candidate cooperating mutations can be easily 
studied and putative synthetic lethal interactions can be validated. Moreover, this approach 
will allow for pre-clinical studies consisting of cohorts of mice that better represent the 
genetic heterogeneity of human cancers (Figure 2A). One can even envision combining 
comprehensive genomic characterization of tumors from individual patients with the rapid 
generation of personalized GEMMs, nGEMMs or cell-based xenografts. In vivo models 
carrying the exact complement of driver mutations from a given patient’s tumor could then 
be screened with conventional or experimental anti-cancer agents to identify the most 
effective therapies.
Somatic genome engineering
As outlined above, the efficiency of genome editing by CRISPR-Cas9 makes the process of 
germline and ES cell line genetic manipulation more rapid and more powerful. The power of 
the system is even more evident in the ability to perform somatic genome editing ex vivo and 
in vivo.
Ex vivo CRISPR-based somatic genome editing for modeling cancer in vivo
Three recent studies have demonstrated the power of CRISPR-based ex vivo somatic 
genome editing for rapid modeling of cooperating mutations and the generation of mouse 
models of haematopoietic malignancies32,44,45. The Pelletier group demonstrated efficient 
ex vivo editing of the Trp53 tumor suppressor gene in Arf−/−Eμ-Myc lymphomas that were 
subsequently transplanted into syngeneic mice to show that Arf−/−Eμ-Myc cells lacking p53 
are substantially enriched upon treatment with doxorubicin32. Using a similar approach, the 
Lowe laboratory utilized ex vivo CRISPR-mediated disruption of the Mll3 (also known as 
Kmt2c) tumor suppressor gene in shNf1;Trp53−/− primary mouse haematopoietic stem and 
progenitor cells (HSPCs) to demonstrate that Mll3 is a haploinsufficient tumor suppressor in 
acute myeloid leukemia (AML)44. The Ebert group employed the CRISPR-Cas9 system to 
rapidly generate mouse models of AML by lentiviral-mediated ex vivo editing of single or 
multiple genes in primary mouse haematopoietic stem and progenitor cells45. These three 
studies highlight the potential of the CRISPR-Cas9 system for ex vivo somatic genome 
editing of primary cells, which can be further exploited for the rapid generation of mouse 
models of a variety of human malignancies (Figure 2B).
In vivo CRISPR-based somatic genome editing for modeling cancer
To explore the use of the CRISPR-Cas9 system for directly mutating genes in living 
animals, our laboratory utilized hydrodynamic gene transfer to simultaneously deliver 
plasmids encoding Cas9 and sgRNAs targeting the Pten and Trp53 tumor suppressor genes 
to hepatocytes in vivo46. Strikingly, delivery of these CRISPR plasmids to the hepatocytes 
of adult wild-type mice was sufficient to induce liver tumors with identical histopathology to 
those observed in Ptenfl/fl;Trp53fl/fl GEMMs, in which tumors were initiated via delivery of 
adenoviruses expressing Cre recombinase. These results strongly suggest that CRISPR-
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mediated somatic genome editing of cancer genes in adult wild-type mice can efficiently 
substitute for traditional GEMMs, at least for some cancer types. Moreover, we further 
demonstrated the feasibility of using the CRISPR-Cas9 system to engineer gain-of-function 
mutations in the livers of adult wild-type mice via the co-delivery of CRISPR components 
and a single-stranded DNA template encoding a mutant form of β-catenin, which resulted in 
the generation of hepatocytes with nuclear β-catenin at a low (0.5%) but detectable 
frequency46.
Moving beyond the liver, we also developed an all-in-one lentivirus simultaneously 
encoding CRISPR components and Cre recombinase. This vector was used to mutate three 
lung cancer tumor suppressor genes in the developing tumors of the well established 
KrasLSL-G12D/+ and KrasLSL-G12D/+;Trp53flox/flox GEMMs of lung cancer40,47,48. 
Intratracheal delivery of all-in-one lentiviruses expressing sgRNAs targeting a panel of 
tumor suppressor genes into KrasLSL-G12D/+ or KrasLSL-G12D/+;Trp53flox/flox mice resulted 
in lung adenocarcinomas with diverse histopathological and molecular features that 
depended on the tumor suppressor gene targeted. Moreover, a large fraction of the lung 
tumors harboured indels in predicted sites within the target genes with no detectable off-
target editing, strongly supporting Cas9 on-target activity for somatic genome editing in 
vivo. In a parallel study, the Ventura group demonstrated the feasibility of using the 
CRISPR-Cas9 system for modeling large oncogenic chromosomal rearrangements (Box 1) 
in wild-type mice in vivo via delivery of an adenovirus encoding Cas9 and two sgRNAs 
designed to induce an Eml4-Alk (echinoderm microtubule associated protein like 4-
anaplastic lymphoma kinase) inversion49,50. Lung tumors developed with complete 
penetrance and were exquisitely sensitive to crizotinib, an inhibitor used to treat human lung 
tumors that harbor this particular oncogenic rearrangement51. Moreover, the fact that the 
Eml4 and Alk loci are separated by ~11 megabases strongly supports the feasibility of the 
CRISPR-Cas9 system for modeling large genomic rearrangements. A subsequent study 
utilizing lentiviruses also demonstrated the ability of the CRISPR-Cas9 system to induce 
chromosomal rearrangements in vivo52. These studies demonstrated the potential of rapidly 
generating mouse models of cancer via somatic genome engineering through delivery of all 
CRISPR components in the form of plasmids or viruses. In addition to these traditional 
DNA- or viral-based delivery methods, recent advances in engineering of non-viral delivery 
materials have made it possible to deliver Cas9-sgRNA protein-RNA complexes53 and 
sgRNA-nanoparticle complexes54 in vivo utilizing cationic lipid-mediated delivery or 7C1 
nanoparticles, respectively. Future advances in materials science and engineering should 
make it possible to implement additional types of non-viral delivery platforms for the 
delivery of Cas9, sgRNAs and HDR donor DNA templates for achieving highly efficient 
genome modification in vivo (non-viral materials extensively reviewed in55).
To further streamline the generation of CRISPR-based somatic mouse models of cancer, the 
Zhang and Sharp laboratories reported the generation of mouse models expressing 
constitutive or Cre-inducible versions of the Cas9 enzyme54. By intratracheally delivering a 
novel adeno-associated virus (AAV) encoding six components: a KrasG12D HDR donor 
DNA template, sgRNAs targeting Kras, serine/threonine kinase 11 (Stk11; also known as 
Lkb1) and Trp53, Cre recombinase and Renilla luciferase into mice expressing the Cre-
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inducible Cas9 allele, they were able to induce lung tumors in adult mice by simultaneously 
disrupting both tumor suppressors and engineering the oncogenic KrasG12D mutation. 
Recently, the Lowe laboratory reported the generation of a highly flexible mouse modeling 
platform consisting of transgenic mice co-expressing doxycycline-inducible alleles of Cas9 
or the Cas9D10A nickase variant52 and constitutively expressed sgRNA cassettes56. Utilizing 
this conditional platform, they demonstrated effective gene editing in vivo with up to 85% 
target gene modification. Moreover, they demonstrated efficient simultaneous biallelic 
modification of up to two genes in vivo using a pair of sgRNAs and the Cas9 nuclease. This 
flexible platform allowed them to accommodate up to six sgRNA cassettes that, when 
combined with the Cas9D10A nickase, led to simultaneous editing of three genes in mouse 
ES cells with high efficiency.
The development of mouse models expressing the Cas9 nuclease and Cas9D10A nickase 
represents a major advancement for CRISPR applications in cancer biology, allowing 
researchers to focus their efforts on delivering single or multiple sgRNAs with or without 
synthetic HDR donor DNA templates utilizing viral and/or non-viral carriers, bypassing the 
need to optimize approaches for co-delivery of this large DNA endonuclease. In addition, 
expression of Cre-inducible or doxycycline-inducible alleles of Cas9 in vivo can be rendered 
tissue-specific via the incorporation of tissue-specific Cre or reverse tetracycline 
transactivator alleles, respectively. Moreover, the development of constitutive and 
conditional mouse models for CRISPR-mediated activation57 or repression58 of gene 
expression (Box 2) will serve as powerful complementary approaches for functionally 
studying both coding and non-coding DNA elements without permanent disruption of the 
endogenous genomic sequence. Beyond the established Mus musculus laboratory organism, 
the flexibility of CRISPR-Cas9 technologies should allow for rapid generation of novel 
animal models of cancer utilizing genetically intractable organisms that better recapitulate 
human tissue architecture and drug metabolism, such as pigs59 and non-human primates60.
Future applications to cancer biology
We envision a new era in cancer biology in which CRISPR-based genome engineering will 
serve as an important conduit between the bench and the bedside (Figure 2C). The 
successful deployment of sophisticated genetic profiling technologies for comprehensive 
characterization of a patient’s tumor is generating detailed roadmaps to instruct the 
development of tailored cell-based or whole animal-based experimental systems. These 
systems will serve as personalized platforms, with which researchers will rapidly and 
systematically identify genotype-specific vulnerabilities and synthetic lethal interactions via 
single or multiplex CRISPR-based and small molecule-based approaches. Moreover, such 
personalized platforms could be studied in parallel to the patients, potentially allowing for 
the rapid identification of resistance mechanisms and the development of strategies to 
overcome such shortcomings61.
Although there are current technical limitations to the use of CRISPR-Cas9 for targeting 
cancer genes in human patients as a therapeutic strategy, the prospects of this form of gene 
therapy are nonetheless very exciting. Recent work has demonstrated the potential of this 
technology to permanently correct genetic mutations in vivo in the adult liver of mouse 
Sánchez-Rivera and Jacks Page 7
Nat Rev Cancer. Author manuscript; available in PMC 2015 August 10.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
models of a hereditary genetic disease via HDR, successfully alleviating aspects of the 
disorder62. Therefore, future advancements of this technology for increasing the efficiency 
of editing and delivery of CRISPR-Cas9 components utilizing both viral and non-viral 
delivery vehicles will allow for therapeutic genetic correction of single or multiple driver 
mutations. In addition to permanently correcting cancer-associated mutations, the CRISPR-
Cas9 system could be employed for precise ex vivo engineering of immune cells for 
immunotherapeutic applications. For example, the CRISPR-Cas9 system could be utilized 
for the development of novel chimeric antigen receptor (CAR)-modified T cells63, in which 
the CAR is precisely inserted into a safe harbor locus64.
Ever since the Doudna and Charpentier groups demonstrated the potential of the CRISPR-
Cas9 system as a powerful RNA-programmed genome editing platform23, the field of 
genome engineering has rapidly undergone a scientific revolution that promises to transform 
nearly every aspect of basic biological and biomedical research. The application of this 
technology to several aspects of cancer biology, ranging from basic research to clinical and 
translational applications, offers numerous exciting opportunities for better understanding 
and potentially treating this devastating disease.
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Box 1
Potential applications of the CRISPR-Cas9 system in cancer biology
The flexibility and modularity of the CRISPR-Cas9 system has led to the development of 
numerous genome engineering applications, most of which have been carried out 
successfully in cell culture systems. Many of these can also be adapted for use in vivo 
(see the figure). The power of this technology can be harnessed for rapidly and precisely 
engineering both loss-of-function (LOF) (part a of the figure) and gain-of-function 
(GOF) (part b of the figure) mutations in tumor suppressor genes, oncogenes and other 
modulators of cellular transformation or drug response. For example, Toshiro Sato’s 
group recently demonstrated the utility of the CRISPR-Cas9 system for systematically 
engineering both LOF and GOF mutations in untransformed human intestinal organoids 
in order to model human colorectal cancer (CRC)65. Remarkably, the serial introduction 
of five independent mutations frequently associated with human CRC (three LOF 
mutations and two GOF mutations) did not fully recapitulate the tumorigenic and 
metastatic characteristics of the human disease, suggesting that additional secondary 
genetic and/or epigenetic events are required for full malignancy65. In addition, the 
ability to multiplex the CRISPR-Cas9 system offers the opportunity to investigate 
combinatorial vulnerabilities in cancer cells, as well as systematically test epistatic 
relationships and synthetic lethal interactions (part a of the figure). This technology also 
allows for generating endogenous conditional alleles based on site-specific 
recombinases39, tagging endogenous alleles39, and interrogating non-coding DNA 
elements66 (part b of the figure). The CRISPR-Cas9 system can also be utilized to trigger 
two distant DSBs in the same or different chromosomes, leading to inversion, deletion or 
translocation of the target or translocation of the target sequences, respectively (part c of 
the figure). This approach has been shown to be efficient in cells67–74 and in vivo49,75.
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Box 2
Potential applications of dCas9-effector fusions in cancer biology
The ability of Cas9 to bind in a specific RNA-dependent fashion can be uncoupled from 
its nuclease activity by mutating its HNH and RuvC-like catalytic domains. This 
catalytically inactive form of Cas9, often referred to as dead Cas9 (dCas9), retains its 
RNA-guided DNA binding activity without any detectable DNA endonuclease activity23. 
A series of studies have demonstrated the power of dCas9-effector fusions (see the 
figure) for reversible transcriptional repression58,76,77 or activation25,57,58,76–82 of 
endogenous coding and non-coding genes. In addition, the use of scaffold RNAs that 
encode both targeting and effector-recruitment functions can be utilized for simultaneous 
multiplex gene repression and activation within a single cell83.
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Box 3
High-throughput genetic screens using CRISPR-Cas9
The flexibility of the CRISPR-Cas9 technology has been recently exploited for carrying 
out high-throughput CRISPR screens using the Cas9 nuclease33,84–87 and dCas9-
effectors77,82 for the systematic identification of genes involved in a variety of biological 
phenotypes (see the figure). The groups of David Sabatini and Eric Lander84 designed 
and utilized a library of ~73,000 sgRNAs targeting human genes to screen for genes 
involved in the DNA-mismatch repair pathway (MMR) in the presence of the nucleotide 
analogue 6-thioguanine (6-TG) and for genes whose disruption conferred resistance to 
the topoisomerase IIA (TOP2A) poison etoposide. Strikingly, both CRISPR screens 
demonstrated a very high signal-to-noise ratio with the top scoring sgRNAs from each 
screen targeting genes involved in the MMR pathway and TOP2A itself, respectively. In 
a parallel study, the group of Feng Zhang33 generated and screened a library of ~65,000 
sgRNAs targeting human genes and successfully identified essential genes in both cancer 
cell lines and pluripotent stem cells. Moreover, they utilized this library for performing a 
positive selection screen in melanoma cell lines to uncover genes whose deletion 
mediates resistance to the BRAF-V600Einhibitor vemurafenib, successfully identifying 
several known and novel candidates mediating resistance to this targeted therapy. 
Additional contemporaneous studies by Koike-Yusa et al.85 and Zhou et al.86 
successfully demonstrated the broad applicability of pooled CRISPR-based screening 
technologies for identifying host factors mediating toxin susceptibility in mouse 
embryonic stem cells and human cells, respectively. In addition to CRISPR-based 
screens utilizing the Cas9 nuclease, Jonathan Weissman’s group77 adapted dCas9-based 
activators and repressors to carry out powerful complementary genome-wide gene 
activation and repression screens, respectively. A subsequent study by Feng Zhang’s 
laboratory82 also demonstrated the successful adaptation of dCas9-based activators for 
genome-wide gene activation screens. Notably, Feng Zhang’s group also demonstrated 
the feasibility of identifying mediators of vemurafenib resistance. These landmark studies 
have demonstrated the feasibility of carrying out pooled high-throughput screens utilizing 
CRISPR-Cas9 technologies to uncover genes mediating a variety of biological 
phenotypes, including uncovering cancer cell vulnerabilities and mechanisms of 
therapeutic response and resistance. In addition to in vitro screens, the Zhang and Sharp 
laboratories recently demonstrated the utility of the CRISPR-Cas9 system for performing 
genome-wide in vivo screens to uncover genes involved in tumor progression and 
metastasis87.
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Figure 1. Genome engineering utilizing the CRISPR-Cas9 system
a | DNA double-strand breaks (DSBs) can be repaired by two cellular DNA repair pathways: 
the non-homologous end joining (NHEJ) pathway or the homology-directed repair (HDR) 
pathway. Repair via the NHEJ pathway, which is error-prone, frequently leads to insertion 
or deletion mutations (indels) that can lead to disrupting frameshift mutations and the 
generation of premature stop codons. Alternatively, in the presence of an exogenous donor 
DNA template, the DSB can be repaired via the HDR pathway, which can be utilized for 
engineering precise DNA modifications. b | The S. pyogenes-derived Cas9 RNA-guided 
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DNA endonuclease is localized to a specific DNA sequence via a single guide RNA 
(sgRNA) sequence, which base-pairs with a specific target sequence that is adjacent to a 
protospacer adjacent motif (PAM) sequence in the form of NGG or NAG. Cas9-mediated 
induction of a DSB in the DNA target sequence leads to indel mutations via NHEJ or 
precise gene modification via HDR.
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Figure 2. Applications of the CRISPR-Cas9 system in cancer biology
a | CRISPR-mediated genome engineering of embryonic stem (ES) cells or genetically 
engineered mouse model (GEMM)-derived ES cells can be utilized for rapidly generating 
novel GEMMs or non-germline GEMMs (nGEMMs) of cancer harbouring multiple genetic 
alterations, such as constitutive or conditional knockout and knock-in alleles, endogenous 
synthetic tags or reporters, non-coding single nucleotide polymorphisms (SNPs) and 
genomic rearrangements, as well as a combination of all of these via re-engineering of ES 
cells or multiplex CRISPR-mediated genome engineering. b | CRISPR-mediated somatic 
genome engineering in vivo can be utilized to rapidly generate cohorts of tumor-bearing 
mice for studying both basic and translational aspects of cancer biology. For example, the 
CRISPR-Cas9 system can be deployed in vivo for generating cohorts of personalized mice 
based on the exact complement of mutations observed in individual patients. c | The 
CRISPR-Cas9 system can serve as an important conduit between the bench and the bedside. 
The combination of sophisticated molecular profiling technologies with CRISPR-based 
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genome engineering technologies will allow researchers to generate personalized 
experimental platforms that can be utilized for rapidly and systematically identifying novel 
genotype-specific vulnerabilities through a battery of cell-based and in vivo assays.
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Figure 3. 
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